Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytodyn Inc
(OP:
CYDY
)
0.1181
+0.0018 (+1.55%)
Streaming Delayed Price
Updated: 3:59 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cytodyn Inc
< Previous
1
2
3
Next >
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
November 04, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
October 30, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
October 08, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
October 07, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
October 04, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
September 24, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
September 2024 Letter to Shareholders
September 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
August 23, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
August 12, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Settlement with Amarex Clinical Research LLC
July 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
June 27, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
May 2024 Letter to Shareholders
May 16, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
January 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
November 2023 Letter to Shareholders
November 03, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Appointment of Additional Directors with Industry Experience
October 20, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
August 11, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
August 10, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY
March 18, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From
CytoDyn Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.